Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04684602 · ClinicalTrials.gov registry record · Phase 1

Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions

A Phase 1 study of Autoimmune Diseases and Sexual Dysfunction, sponsored by Thomas Advanced Medical.

Recruiting
Registry status
Phase 1
Development phase
5,000
Enrollment target
1
Study location

NCT04684602: Recruiting Phase 1 study of Autoimmune Diseases and Sexual Dysfunction, sponsored by Thomas Advanced Medical.

NCT04684602 is a Phase 1 study of Autoimmune Diseases and Sexual Dysfunction that is actively recruiting participants, run by Thomas Advanced Medical. The registered enrollment target is 5,000 participants, above the 778-participant average among 25 other Autoimmune Diseases trials with a reported enrollment target (543% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04684602, a Phase 1 study of Autoimmune Diseases and Sexual Dysfunction, is actively recruiting participants, sponsored by Thomas Advanced Medical.

RECRUITING
Registry status
Phase 1
Development phase
5,000 participants
Enrollment target
1
Study location

Study Summary

This multi-arm, multi-site study investigates the safety, tolerability, and efficacy of stem cell therapy for the treatment of various acute and chronic conditions. Clinically observed initial findings and an extensive body of research indicate regenerative treatments are both safe and effective for the treatment of multiple conditions.

Primary Outcome

General Health Outcome Instrument used to derive a simple psychometric score for health related quality of life which provides scores on various dimensions or items describing the systems. The score is derived by adding the unweighted response order of each question, with a lower score denoting a better quality of life.

Interventions

  • BIOLOGICAL PrimePro™/ PrimeMSK™

Study Locations (1)

California

  • Southern California Hospital at Culver City / Southern California Hospital at Hollywood / Multiple US-based Sub-Investigator Sites - Culver City

Trial Details

FieldValue
Enrollment Target 5,000 participants
Start Date 2020-07-09
Est. Completion 2030-12-09
Phase Phase 1
Thomas Advanced Medical

2 total trials

What NCT04684602 shows while recruiting

NCT04684602 is an interventional study that assigns participants to a tested intervention. Its 5,000 participants enrollment target places it among the larger protocols in the corpus, above the 778-participant average among 25 other Autoimmune Diseases trials with a reported enrollment target (543% higher).

The record links to 10 conditions, with Autoimmune Diseases appearing as the primary indexed condition, and to 1 intervention - of which PrimePro™/ PrimeMSK™ is the first listed.

NCT04684602 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT04684602 about?

NCT04684602 is a clinical study titled "Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions". This multi-arm, multi-site study investigates the safety, tolerability, and efficacy of stem cell therapy for the treatment of various acute and chronic conditions. Clinically observed initial findings and an extensive body of research indicate regenerative treatments are both safe and effective for...

What is the current status of trial NCT04684602?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 5,000 participants. The study started on 2020-07-09. Estimated completion is 2030-12-09.

What conditions does trial NCT04684602 study?

This clinical trial studies the following conditions: Autoimmune Diseases, Sexual Dysfunction, Diabetes Complications, Neurologic Disorders, Cardiovascular Disorders.

What interventions are being tested in trial NCT04684602?

The interventions under investigation include: PrimePro™/ PrimeMSK™ (BIOLOGICAL).

Who is sponsoring clinical trial NCT04684602?

This trial is sponsored by Thomas Advanced Medical, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04684602 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Autoimmune Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04684602's enrollment target sits among peer trials

5,000 2nd of 25 the highest of 25 other Autoimmune Diseases trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Autoimmune Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00060541 · 5,000 participants

    Evaluation and Treatment of Neurosurgical Disorders

  • NCT00575081 · 5,000 participants

    Physiological Brain Atlas Development

  • NCT00736749 · 5,000 participants

    Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

  • NCT00900198 · 5,000 participants

    Collection of Tissue Samples for Cancer Research

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04684602, the US trial registry maintained by the National Library of Medicine. NCT04684602 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.